Cell fusion research at Johns Hopkins could lead to improved remedies for muscular dystrophy Researchers in Johns Hopkins established a high-effectiveness cell-cell fusion program, providing a new model to review how fusion works. The scientists demonstrated that fusion between two cells is not equivalent and mutual as some assumed, but, rather, is set up and driven by one of the fusion partners anabolic steroid . The discovery, they say, may lead to improved treatments for muscular dystrophy, since muscles regeneration depends on cell fusion to create muscle fibers which contain hundreds or also thousands of nuclei. The study reveals two critical elements that have to be there for cell fusion to occur, clarifies Elizabeth Chen, Ph.D., a co-employee professor of molecular genetics and biology in the Johns Hopkins University Institute for Basic Biomedical Sciences.
‘Our portfolio of items and promising hematology and immune-inflammatory pipeline position us to create an increasingly meaningful impact on the lives of sufferers experiencing serious unmet medical conditions. By combining operational excellence with innovative science, we are strategically positioned to create sustained long-term growth.’ Product Sales Performance Non-GAAP total revenue was a record $850.4 million for the quarter ended June 30, 2010, an increase of 36 % from 2009. GAAP total income was $852.7 million for the quarter ended June 30, 2010. The increase in total revenue was driven by global market share gains and improved duration of therapy of REVLIMID.